 |
|
|
| |
Switching to F/TAF (Tenofovir Alafenamide) from F/TDF (Tenofovir DF)
based Regimen Study 311-1089: 48-Week Data
|
| |
| |
Reported by Jules Levin
CROI 2016 Feb 21-24, Boston MA
Joel Gallant1, Eric Daar2, Francois Raffi3, Cynthia Brinson4,
Peter Ruane5, Edwin DeJesus6, Mingjin Yan 7, Andrew Plummer7, Andrew Cheng7, Martin S Rhee7
1Southwest CARE Center, Santa Fe, NM; 2Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; 3CHU Hotel Dieu-CHU De Nantes, Nantes, France; 4Central Texas Clinical Research, Austin, TX; 5Ruane Medical and Liver Health Institute, Los Angeles, CA; 6Orlando Immunology Center, Orlando, FL; 7Gilead Sciences, Foster City, CA
WEBCAST link: http://www.croiwebcasts.org/console/player/29457?mediaType=audio&
|
| |
|
|
|
|
|
